title: [A case of HER2-positive breast cancer for which preoperative chemotherapy with pertuzumab resulted in a pathological complete response].
abstract: A right breast tumor was identified during screening in a 56-year-old woman, and she was then diagnosed with Stage II B breast cancer (T2N1M0) of Luminal -HER2 type. She was treated with preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel followed by epirubicin, cyclophosphamide, and fluorouracil. She was judged to have achieved a clinical complete response after 4 courses of pertuzumab, trastuzumab, and docetaxel, and she then underwent partial resection of the right breast and sentinel lymph node dissection. Pathological examination revealed that a pathological complete response was achieved. Combination therapy with pertuzumab, trastuzumab, and docetaxel seems to be a useful preoperative chemotherapy regimen for HER2-positive breast cancer.
authors.affiliation: Breast Center, Bell Land General Hospital.
authors.forename: Hajime
authors.initials: H
authors.lastname: Abe
authors.forename: Keiichi
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Kori
authors.initials: K
authors.lastname: Yoneda
authors.forename: Masao
authors.initials: M
authors.lastname: Ogawa
authors.forename: Masayasu
authors.initials: M
authors.lastname: Kawasaki
authors.forename: Genichiro
authors.initials: G
authors.lastname: Yoneda
authors.forename: Masako
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Masao
authors.initials: M
authors.lastname: Kameyama
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C485206:pertuzumab